Humana — Oct 30, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000049071-24-000051
Showing in the filing
Diluted earnings per common share (GAAP)
“at least $12.89”
Period
FY2024
Measure
GAAP-tied
Source
Guidance table
All guidance in this release · 28
EPS, GAAP basis for FY2024
“at least $12.89”
Diluted earnings per share (Adjusted non-GAAP) for FY2024
“at least $16.00”
EPS, Adjusted basis for FY2024
“at least $16.00”
Individual Medicare Advantage annual members… for FY2024
“approximately 265,000, or approximately 5 percent”
Diluted earnings per common share (GAAP) for FY2024
“at least $12.89”
Total Revenues: Consolidated for FY2024
“no change”
Change in year-end medical membership from p… for FY2024
“no change”
Total Revenues, Consolidated, GAAP for FY2024
“approximately $116 billion”
Total Revenues: CenterWell segment for FY2024
“no change”
Benefit Ratio: Insurance segment for FY2024
“no change”
Segment Results: Insurance segment income fr… for FY2024
“no change”
Total Revenues, Insurance segment, GAAP for FY2024
“approximately $112 billion”
Total Revenues, CenterWell segment, GAAP for FY2024
“approximately $19 billion”
Change in year-end medical membership from p… for FY2024
“Growth of approximately 265,000”
Change in year-end medical membership from p… for FY2024
“Growth of approximately 35,000”
Change in year-end medical membership, Medic… for FY2024
“Decline of approximately 600,000”
Change in year-end medical membership from p… for FY2024
“Growth of approximately 200,000”
Benefit Ratio, Insurance segment, GAAP for FY2024
“approximately 90%”
Operating Cost Ratio, Consolidated, GAAP for FY2024
“approximately 11.4%”
Operating Cost Ratio: Consolidated for FY2024
“no change”
Insurance segment income from operations, GAAP for FY2024
“approximately $1.1 billion”
Insurance segment income from operations, No… for FY2024
“approximately $1.2 billion”
CenterWell segment income from operations, N… for FY2024
“approximately $1.4 billion”
Effective Tax Rate, GAAP for FY2024
“approximately 25.2%”
Effective Tax Rate, Non-GAAP for FY2024
“approximately 25.0%”
Weighted Avg. Share Count for Diluted EPS for FY2024
“approximately 121 million”
Cash flows from operations, GAAP for FY2024
“approximately $2.75 billion”
Capital expenditures, GAAP for FY2024
“approximately $600 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com. 14 Humana Inc. Full Year 2024 Projections - As of October 30, 2024 Current Guidance Prior Guidance Diluted earnings per common share GAAP: at least $12.89 GAAP: approximately $12.81 Non-GAAP: at least $16.00 Non-GAAP: approximately $16.00 Total Revenues Consolidated no change GAAP: approximately $116 billion Consolidated and segment level revenue projections include expected investment income. Segment level revenues include amounts that eliminate in consolidation. Insurance segment no change GAAP: approximately $112 billion CenterWell segment no change GAAP: approximately $19 billion Change in year-end medical membership from prior year-end Individual Medicare Advantage Growth of approximately 265,000 Growth of approximately 225,000 Group Medicare Advantage Growth of approximately 35,000 Growth of approximately 45,000 Medicare stand-alone PDP no change Decline of approximately 600,000 State-based contracts Growth of approximately 200,000 Growth of approximately 250,000 State-based contracts guidance includes membership in Florida, Illinois, Indiana, Kentucky, Louisiana, Ohio, Oklahoma, South Carolina, and Wisconsin. Benefit Ratio Insurance segment no change GAAP: approximately 90% Ratio calculation: benefits expense as a percent of premiums revenues. Operating Cost Ratio Consolidated no change GAAP: approximately 11.4% Ratio calcul
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.